S Dicuonzo1, M C Leonardi1, D P Rojas1, B A Jereczek-Fossa1,2, S Raimondi3, G Corrao4,5, V Bagnardi6, M A Gerardi1, A Morra1, M A Zerella1, M Zaffaroni1, F Pansini7, F Cattani7, R Luraschi7, C Fodor1, P Veronesi2,8, R Orecchia9. 1. Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, via Ripamonti, 435, 20141, Milan, Italy. 2. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. 3. Molecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. 4. Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, via Ripamonti, 435, 20141, Milan, Italy. giulia.corrao@ieo.it. 5. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. giulia.corrao@ieo.it. 6. Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy. 7. Unit of Medical Physics, IEO, European Institute of Oncology IRCCS, Milan, Italy. 8. Division of Breast Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy. 9. Scientific Directorate, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Abstract
AIMS: To report toxicity of a hypofractionated scheme of whole-breast (WB) intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) to the tumor bed (TB) using Tomotherapy® with Direct modality. METHODS: Patients with early breast cancer, undergoing radiotherapy (RT) in 15 daily fractions to WB (prescription dose 40.05 Gy) and SIB to the TB (48 Gy), between 2013 and 2017, was analyzed. Primary endpoint was acute and intermediate toxicity assessed at the end and within 6 months from RT, according to Radiation Therapy Oncology Group (RTOG) scale. Secondary endpoints included early chronic toxicity at 12-months follow-up, using the Late Effects Normal Tissue Task Subjective, Objective, Management, and Analytic (LENT-SOMA) scale, and cosmesis using Harvard criteria. RESULTS: The study population was of 287 patients. Acute and intermediate toxicity was collected among 183 patients with data available at the end of RT and within 6 months, 85 (46%) experienced G2 toxicity and 84 (46%) G1 toxicity, while 14 (8%) did not report toxicity at any time. A significant reduction of any grade toxicity was observed between the two time points, with the majority of patients reporting no clinically relevant toxicity at 6 months. At univariate analysis, age < 40 years, breast volume > 1000 cm3 and Dmax ≤ 115% of prescription dose were predictive factors of clinically relevant acute toxicity (G ≥ 2) at any time. At multivariable analysis, only age and breast volume were confirmed as predictive factors, with Relative Risks (95% Confidence Intervals): 2.02 (1.13-3.63) and 1.84 (1.26-2.67), respectively. At 12-month follow-up, 113 patients had complete information on any toxicity with 53% of toxicity G < 2, while cosmetic evaluation, available for 102 patients, reported a good-excellent result for 86% of patients. CONCLUSIONS: Hypofractionated WB IMRT with a SIB to the TB, delivered with TomoDirect modality, is safe and well-tolerated. Most patients reported no toxicity after 6 months and good-excellent cosmesis. Predictive factors of clinically relevant toxicity might be considered during treatment planning in order to further reduce side effects.
AIMS: To report toxicity of a hypofractionated scheme of whole-breast (WB) intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) to the tumor bed (TB) using Tomotherapy® with Direct modality. METHODS: Patients with early breast cancer, undergoing radiotherapy (RT) in 15 daily fractions to WB (prescription dose 40.05 Gy) and SIB to the TB (48 Gy), between 2013 and 2017, was analyzed. Primary endpoint was acute and intermediate toxicity assessed at the end and within 6 months from RT, according to Radiation Therapy Oncology Group (RTOG) scale. Secondary endpoints included early chronic toxicity at 12-months follow-up, using the Late Effects Normal Tissue Task Subjective, Objective, Management, and Analytic (LENT-SOMA) scale, and cosmesis using Harvard criteria. RESULTS: The study population was of 287 patients. Acute and intermediate toxicity was collected among 183 patients with data available at the end of RT and within 6 months, 85 (46%) experienced G2 toxicity and 84 (46%) G1 toxicity, while 14 (8%) did not report toxicity at any time. A significant reduction of any grade toxicity was observed between the two time points, with the majority of patients reporting no clinically relevant toxicity at 6 months. At univariate analysis, age < 40 years, breast volume > 1000 cm3 and Dmax ≤ 115% of prescription dose were predictive factors of clinically relevant acute toxicity (G ≥ 2) at any time. At multivariable analysis, only age and breast volume were confirmed as predictive factors, with Relative Risks (95% Confidence Intervals): 2.02 (1.13-3.63) and 1.84 (1.26-2.67), respectively. At 12-month follow-up, 113 patients had complete information on any toxicity with 53% of toxicity G < 2, while cosmetic evaluation, available for 102 patients, reported a good-excellent result for 86% of patients. CONCLUSIONS: Hypofractionated WB IMRT with a SIB to the TB, delivered with TomoDirect modality, is safe and well-tolerated. Most patients reported no toxicity after 6 months and good-excellent cosmesis. Predictive factors of clinically relevant toxicity might be considered during treatment planning in order to further reduce side effects.
Entities:
Keywords:
Early breast cancer; Hypofractionated radiotherapy; Simultaneous integrated boost; Toxicity
Authors: Simone L Alford; Georgina N Prassas; Cathy R Vogelesang; Heather J Leggett; Chris S Hamilton Journal: J Med Imaging Radiat Oncol Date: 2013-03-26 Impact factor: 1.735
Authors: Maria Carmen De Santis; Francesca Bonfantini; Francesca Di Salvo; Alba Fiorentino; Michela Dispinzieri; Mariangela Caputo; Serena Di Cosimo; Gabriella Mariani; Massimiliano Gennaro; Vito Cosentino; Milena Sant; Emanuele Pignoli; Riccardo Valdagni; Laura Lozza Journal: Clin Breast Cancer Date: 2018-04-22 Impact factor: 3.225
Authors: Kathrin Dellas; Reinhard Vonthein; Jörg Zimmer; Stefan Dinges; Alexander D Boicev; Peter Andreas; Dorothea Fischer; Cornelia Winkler; Andreas Ziegler; Jürgen Dunst Journal: Strahlenther Onkol Date: 2014-04-16 Impact factor: 3.621
Authors: Adrian Murray Brunt; Joanne S Haviland; Duncan A Wheatley; Mark A Sydenham; Abdulla Alhasso; David J Bloomfield; Charlie Chan; Mark Churn; Susan Cleator; Charlotte E Coles; Andrew Goodman; Adrian Harnett; Penelope Hopwood; Anna M Kirby; Cliona C Kirwan; Carolyn Morris; Zohal Nabi; Elinor Sawyer; Navita Somaiah; Liba Stones; Isabel Syndikus; Judith M Bliss; John R Yarnold Journal: Lancet Date: 2020-04-28 Impact factor: 202.731